Latest Headlines

Latest Headlines

J&J's Stelara may be under fire in psoriasis, but it's positioned to score elsewhere

Novartis is aiming to distinguish new psoriasis med Cosentyx from the rest of the next-gen field by building up its label, adding nods for conditions including ankylosing spondylitis. But it'll have some competition in that space, too.

From the pharma C-suite: Novartis on Asia, emerging markets in Q2

FiercePharmaAsia  combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.

Top 10 pharma companies in social media

Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....

For Entresto rollout, Novartis marketing mixes tried-and-true with new-and-different

With all the excitement about Novartis' new heart failure drug Entresto, the usual question that follows an FDA approval--how will they actually sell it--might seem irrelevant. But the former LCZ696's path to blockbuster sales isn't without its obstacles, and the Swiss drugmaker isn't leaving much to chance.

Novartis' Sandoz puts India plant on chopping block

Novartis CEO Joe Jimenez said in March the company would have another go at significant cost cuts in the wake of its asset swap with GlaxoSmithKline. Manufacturing was one area where it expected to tighten up, and a plant in India is now on the chopping block along with 170 jobs.

Novartis steps into wearables with app for Apple Watch, Android Wear

Novartis has opened a new front in its push into digital health. The latest move sees the Big Pharma bring its navigation app for visually impaired people to Apple and Google's smartwatch platforms.

Stormy Australia hearings on transfer pricing by drug firms invoke Sergeant Schultz

Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.

Feds demand $3.4B in damages, fines in Novartis kickback case

Kickback allegations against Novartis just got scarier. After years of investigating the Swiss drugmaker, the Justice Department and 11 states are demanding almost $3.4 billion in damages and fines in a False Claims Act lawsuit nearing trial.

No artful tax dodging here, drug firms tell Australia transfer-price inquiry

We checked and everything is done correctly on our tax obligations, 9 drug companies said in separate submissions ahead of testimony on July 1 to an Australian Senate inquiry on tax avoidance.

Novartis shells out $200M-plus for Spinifex and its mid-stage pain drug

Novartis snapped up tiny Spinifex and its mid-stage pain drug in a $200 million-plus deal.